Biotech

Theralase Technologies shared new results from its patented and lead anti-cancer drug TLD-1433, in fighting a human pharyngeal carcinoma cell line.

Theralase Technologies (TSXV:TLT; OTCQX:TLTFF) shared new results from its patented and lead anti-cancer drug TLD-1433, in fighting a human pharyngeal carcinoma cell line.
As quoted in the press release:

In 2016, according to the American Society of Clinical Oncology (“ASCO“), an estimated 49,670 adults (35,720 men and 13,950 women) in the United States will be diagnosed with oral and oropharyngeal cancer. Rates of these cancers are more than twice as high in men, as in women. Cancer of the oral cavity is the ninth most common cancer among men. The average age of diagnosis is 62.
The overall 5-year survival rate for people with oral or oropharyngeal cancer is 64%.
It is estimated that 9,700 deaths (7,000 men and 2,700 women) from these 2 diseases will occur this year.

Click here to read the full press release.

Source: www.accesswire.com

MARKETS

Markets
TSX19028.86+167.50
TSXV623.23+5.97
DOW31097.26+321.83
S&P 5003825.33+39.95
NASD11127.85+99.11
ASX6612.60+72.70

COMMODITIES

Commodities
Gold1803.75-5.35
Silver19.87-0.12
Copper3.51-0.09
Palladium1933.20-4.30
Platinum880.37-3.65
Oil108.39-0.04
Heating Oil3.90-0.04
Natural Gas5.75+0.02

DOWNLOAD FREE REPORTS

×